Search Results - "SANDMAIER, B. M"

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation by Walter, R B, Gyurkocza, B, Storer, B E, Godwin, C D, Pagel, J M, Buckley, S A, Sorror, M L, Wood, B L, Storb, R, Appelbaum, F R, Sandmaier, B M

“…Minimal residual disease (MRD) is associated with adverse outcome in acute myeloid leukemia (AML) after myeloablative (MA) hematopoietic cell transplantation…”
Get full text

Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning by Baron, F, Sandmaier, B M

“…Allogeneic hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning has been extensively evaluated in patients with hematologic…”
Get full text

Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis by Ustun, C, Giannotti, F, Zhang, M-J, Wang, H-L, Brunstein, C, Labopin, M, Rocha, V, de Lima, M, Baron, F, Sandmaier, B M, Eapen, M, Gluckman, E, Nagler, A, Weisdorf, D J, Ruggeri, A

“…Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival…”
Get full text

Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity by Aki, S Z, Inamoto, Y, Carpenter, P A, Storer, B E, Sandmaier, B M, Lee, S J, Martin, P J, Flowers, M E D

“…The 2005 NIH chronic GVHD (cGVHD) organ severity is based on the assessment of current status regardless of whether abnormalities are due to GVHD. The score…”
Get full text

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis by Scott, B L, Sandmaier, B M, Storer, B, Maris, M B, Sorror, M L, Maloney, D G, Chauncey, T R, Storb, R, Deeg, H J

“…Transplant outcome was analyzed in 150 patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia transformed from MDS (tAML) conditioned with…”
Get full text

Chronic Kidney Disease Following Non‐Myeloablative Hematopoietic Cell Transplantation by Weiss, A. S., Sandmaier, B. M., Storer, B., Storb, R., McSweeney, P. A., Parikh, C. R.

“…Chronic kidney disease (CKD) following myeloablative allogeneic hematopoietic cell transplantation (HCT) occurs in 20% of survivors at 1 year and is believed…”
Get full text

Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin by Ostronoff, F, Milano, F, Gooley, T, Gutman, J A, McSweeney, P, Petersen, F B, Sandmaier, B M, Storb, R, Delaney, C

“…Reduced-intensity conditioning (RIC) regimens in cord blood transplant (CBT) are increasingly utilized for older patients and those with comorbidities…”
Get full text

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center by Bensinger, W, Rotta, M, Storer, B, Chauncey, T, Holmberg, L, Becker, P, Sandmaier, B M, Storb, R, Maloney, D

“…Allogeneic stem cell transplant for multiple myeloma (MM) is one treatment associated with long-term disease-free survival. The high incidence of…”
Get full text

High doses of transplanted CD34 cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation by BARON, F, MARIS, M. B, HEIMFELD, S, STORER, B. E, SANDMAIER, B. M, PANSE, J. P, CHAUNCEY, T. R, SORROR, M, LITTLE, M.-T, MALONEY, D. G, STORB, R

“…This report examines the impact of graft composition on outcomes in 130 patients with hematological malignancies given unrelated donor…”
Get full text

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD by Bethge, W A, Kerbauy, F R, Santos, E B, Gooley, T, Storb, R, Sandmaier, B M

“…Extracorporeal photopheresis (ECP) and the purine analog pentostatin exert potent immunomodulatory effects. We evaluated the use of these treatment modalities…”
Get full text

Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil by Li, H., Mager, D.E., Sandmaier, B.M., Maloney, D.G., Bemer, M.J., McCune, J.S.

“…We sought to create a population pharmacokinetic model for total mycophenolic acid (MPA), to study the effects of different covariates on MPA pharmacokinetics,…”
Get full text

Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation by Thakar, M S, Kurre, P, Storb, R, Kletzel, M, Frangoul, H, Pulsipher, M A, Leisenring, W, Flowers, M E D, Sandmaier, B M, Woolfrey, A, Kiem, H-P

“…A nonmyeloablative conditioning regimen consisting of fludarabine (FLU) and 2 Gy TBI has been used extensively and with substantial engraftment success without…”
Get full text

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy by Zimmerman, Z, Scott, B L, Gopal, A K, Sandmaier, B M, Maloney, D G, Deeg, H J

“…Allogeneic hematopoietic cell transplantation (HCT) can be curative for both myelodysplastic syndromes (MDS) and lymphoid malignancies. Little is known about…”
Get full text

Allogeneic peripheral blood stem cell graft composition affects early T‐cell chimaerism and later clinical outcomes after non‐myeloablative conditioning by Panse, J. P., Heimfeld, S., Guthrie, K. A., Maris, M. B., Maloney, D. G., Baril, B. B., Little, M.‐T., Chauncey, T. R., Storer, B. E., Storb, R., Sandmaier, B. M.

“…Summary We have studied the influence of cell subsets [CD34, CD3, CD4, CD8, CD14, CD20, natural killer (NK; CD3−/CD56+), NKT (CD3+/CD56+), DC1, and DC2 cells]…”
Get full text

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML by KERBAUY, F. R, STORB, R, EPNER, E. M, CHAUNCEY, T. R, BLUME, K. G, NIEDERWIESER, D, SANDMAIER, B. M, HEGENBART, U, GOOLEY, T, SHIZURU, J, AL-ALI, H. K, RADICH, J. P, MALONEY, D. G, AGURA, E, BRUNO, B

“…A total of 24 patients (median age 58; range, 27-71 years) with chronic myeloid leukemia (CML) in first chronic (CP1) (n=14), second chronic (n=4), or…”
Get full text

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning by FLOWERS, M. E. D, TRAINA, F, STORER, B, MARIS, M, BETHGE, W. A, CARPENTER, P, APPELBAUM, F, STORB, R, SANDMAIER, B. M, MARTIN, P. J

“…The efficacy of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning depends on the balance between the desirable…”
Get full text

Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment by Bethge, W A, Kerbauy, F R, Santos, E, Gooley, T A, Storb, R, Sandmaier, B M

“…Extracorporeal photopheresis (ECP) and the purine analog pentostatin exert potent immunomodulatory effects, but have not been evaluated for their ability to…”
Get full text

Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens by Sala-Torra, O, Martin, P J, Storer, B, Traina, F, Sorror, M L, Storb, R, Sandmaier, B M, Flowers, M E D

“…We previously reported a 25% incidence of serious graft-versus-host disease (GVHD) (that is, acute or chronic GVHD that caused death, lengthy hospitalization…”
Get full text

Cyclophosphamide-Based In Vivo T-Cell Depletion for HLA-Haploidentical Transplantation in Fanconi Anemia by Thakar, M.S., Bonfim, C., Sandmaier, B.M., O'Donnell, P., Ribeiro, L., Gooley, T., Deeg, H.J., Flowers, M.E., Pasquini, R., Storb, R., Woolfrey, A.E., Kiem, H.P.

“…Allogeneic hematopoietic cell transplantation (HCT) is the only known cure for patients with Fanconi anemia (FA) who develop aplasia or leukemia. However,…”
Get full text

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine by HOLMBERG, L. A, OPARIN, D. V, GOOLEY, T, LILLEBY, K, BENSINGER, W, REDDISH, M. A, MACLEAN, G. D, LONGENECKER, B. M, SANDMAIER, B. M

“…The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERATOPE STn-KLH cancer vaccine to ovarian and breast…”
Get full text